http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103484498-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate | 2013-09-04^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-08-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-08-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103484498-B |
| titleOfInvention | A kind of α1the high flux screening cell model of-AR subtype selective antagonists and construction method thereof and application |
| abstract | The invention particularly discloses a kind of α 1 The high flux screening cell model of AR subtype selective antagonists and construction method thereof and application.Described construction method is by α 1 Tri-kinds of hypotype (α of AR 1A ,α 1B ,α 1D ) eukaryon expression plasmid, reporter gene and internal reference plasmid co-transfection host cell, set up and wink turn cell model, successively antagonist to be screened and agonist is added in cell model, after co-culturing a period of time, cell cracks, pyrolysis product carries out uciferase activity mensuration, measures reporter gene and the relative expression quantity of internal reference, evaluates this medicine to α with this 1 Tri-kinds of hypotype: α of AR 1A 、α 1B And α 1D Inhibitory activity.The method is investigated and modelling verification by model stability, undulatory property.Can be used for α 1 The high flux screening of AR subtype selective antagonists, is further useful for screening potential treatment benign prostatic hyperplasia medicine. |
| priorityDate | 2013-09-04^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 203 of 203.